CARCINOMA, NON-SMALL-CELL LUNG

This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…

This trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types.…

This early-phase trial tests whether a special MRI scan using hyperpolarized xenon gas can help doctors plan radiation treatment for non-small cell lung cancer. The goal is to deliver enough radiation to the tumor while avoiding healthy lung tissue, which could reduce side effect…

This phase 3 trial tests QL2107, a biosimilar (copy) of the cancer drug Keytruda, in 122 adults with non-small cell lung cancer that has been surgically removed. The goal is to see if the body processes QL2107 the same way as Keytruda when given as an extra treatment after surger…

This observational study follows Indian adults with resectable non-small cell lung cancer who are prescribed durvalumab as part of their routine care. The goal is to monitor how often patients experience serious side effects, including severe adverse events and other complication…

This study reviews medical records of 250 people with advanced or metastatic non-small cell lung cancer that has a specific change in the EGFR gene. Researchers want to learn about patients' backgrounds, the treatments they receive, and how well those treatments work. The goal is…

This study takes leftover tumor samples from people with EGFR-mutant non-small cell lung cancer and grows them in the lab as cell cultures and organoids. Researchers will test different anti-EGFR drugs on these models to see which ones work best for each type of mutation and expl…